• Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval 
•  Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent designation for primary ITP 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.